Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application to follow in 2026.

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application to follow in 2026.
The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
EU Health Data Space strikes a chord in EU harmonisation plans
Mastering compliance and copyright in healthcare and MedComms
AstraZeneca director says AI must be a “thought partner” in drug discovery